支气管源性癌患者的免疫能力
Immunocompetence of patients with bronchogenic carcinoma.
作者信息
Olkowski Z L, McLaren J R, Mansour K A
出版信息
Ann Thorac Surg. 1976 Jun;21(6):546-51. doi: 10.1016/s0003-4975(10)63927-6.
Patients with lung carcinoma were tested for number of circulating thymus-derived (T-)lymphocytes and lymphocyte cytotoxicity before treatment and following operation or radiation therapy or a combination of the two. The proportion of circulating T-lymphocytes in healthy individuals was 75%, and the T-lymphocyte level was 1, 460 per cubic millimeter. All patients with lung cancer had a significantly decreased percentage and absolute number of T-cells before any treatment. Patients tested six to eight weeks following pneumonectomy or lobectomy showed an increased proportion of circulating T-cells in comparison to pretreatment values. Functional activity of immune lymphocytes as shown by cytotoxicity assay also improved in comparison to pretreatment values. The potential value of tests for immunocompetence is discussed.
对肺癌患者在治疗前以及手术、放疗或两者联合治疗后，检测其循环胸腺来源（T）淋巴细胞数量和淋巴细胞细胞毒性。健康个体中循环T淋巴细胞的比例为75%，T淋巴细胞水平为每立方毫米1460个。所有肺癌患者在任何治疗前T细胞的百分比和绝对数量均显著降低。肺叶切除或肺切除术后6至8周进行检测的患者，其循环T细胞比例相较于治疗前有所增加。与治疗前相比，通过细胞毒性试验显示的免疫淋巴细胞功能活性也有所改善。文中讨论了免疫能力检测的潜在价值。
Zotero 插件